Nursing Cancer Chemotherapy Pharmacology Practice Questions: Chapter 33-34 Humanized monoclonal antibody that binds to HER2 Protein :
Pertuzumab (Perjeta)
Click on the correct answer.
Pertuzumab (Perjeta):
Primarily binds to domain II of HER2
Primarily binds to domain IV of HER2
Both equally
Neither
Pertuzumab (Perjeta):
A humanized monoclonal antibody
Targets (inhibits) extracellular receptor dimerization of HER2 domain II.
Both
Pertuzumab:
Stops ligand -dependent heterodimerization between HER2 and other HER family receptors.
Inhibits ligand-dependent signaling.
Both
Neither
Binding between HER2 overexpressing cells and pertuzumab may induce antibody -dependent cytotoxicity (Cell-Mediated).
True
False
pertuzumab pharmacokinetics:
IV administration, in combination with transtuzumab and docetaxel.
Median half-life: approximately 18 days
Both
Neither
Pertuzumab (Perjeta) clinical use(s):
Treatment of HER2 -positive, locally advanced, inflammatory breast cancer
Treatment of early-stage breast cancer when used in combination with docetaxel and trastuzumab.
Both
Neither
Example(s) of therapeutic regimens for HER2 -positive metastatic breast cancer:
Docetaxel + trastuzumab +/- pertuzumab
Paclitaxel+ trastuzumab +/- pertuzumab
Vinorelbine + trastuzumab +/- pertuzumab
A & B
B & C
A, B & C
Pertuzumab and possible cardiotoxicity:
Reduced left ventricular ejection fraction may occur with some drugs that block HER2 activity.
Assessment of left ventricular ejection fraction (LVEF) should be checked prior to initial pertuzumab (Perjeta) administration and add regular subsequent intervals such as every three months to ensure LVEF is found within normal limits.
Both
Neither
Pertuzumab (Perjeta) administration may result in fetal harm when administered to a pregnant woman.
True
Falls
HER2 protein overexpression is a requirement for identifying patients appropriate for receiving pertuzumab (Perjeta) treatment.
